AHK-Cu

AHK-Cu is a synthetic tripeptide composed of alanine, histidine, and lysine (Ala-His-Lys), complexed with a copper(II) ion through the histidine imidazole nitrogen and the N-terminal amine. The copper-binding architecture parallels that of GHK-Cu, the well-studied endogenous tripeptide. AHK-Cu was developed as a synthetic analog for cosmetic applications, particularly hair-follicle-targeted formulations. It is not an endogenous compound; humans do not naturally produce AHK.

The compound is listed in cosmetic ingredient databases as Copper Tripeptide-3 or AHK Copper and appears in commercial scalp serums, hair-loss formulations, and skin-care products. The chemistry of copper-tripeptide binding is well-characterized: the imidazole side chain of histidine and the N-terminal amine coordinate copper, with additional weaker interactions stabilizing the complex. The structural similarity to GHK-Cu is the source of the cosmetic-market interest.

The research literature is markedly smaller than that for GHK-Cu. The most cited primary work on AHK-Cu hair-follicle effects is the 2007 paper by Pyo and colleagues, which examined AHK-Cu effects on hair-follicle vascularization markers and dermal papilla cells. Subsequent studies have been smaller and have not produced a substantial human-trial database.

The Evidence

Hair-follicle biology. The Pyo et al. study reported that AHK-Cu stimulates VEGF production in cultured dermal papilla cells and promotes vascularization markers in animal models. The mechanism is proposed to operate through copper-mediated lysyl oxidase activation, growth factor modulation, and direct effects on dermal papilla cell signaling.

Skin biology. AHK-Cu has been evaluated for skin-remodeling effects in cosmetic-grade studies, generally with shorter and smaller protocols than the GHK-Cu literature. Effects on collagen synthesis markers, elastin production, and dermal repair have been reported in in vitro and ex vivo settings.

Human clinical trial data. Sparse. Most published work consists of small cosmetic-industry studies of finished product formulations rather than head-to-head trials of AHK-Cu as a defined active. The evidence base does not approach the standard required for FDA marketing authorization for any therapeutic indication.

Regulatory and Legal Status

FDA. No therapeutic approval. Permitted as a cosmetic ingredient in marketed products under standard cosmetic regulatory pathways. No drug approval exists for hair-loss or skin therapeutic indications.

EMA. Similar cosmetic-ingredient status; no medicinal product approval.

INCI. Listed as Copper Tripeptide-3 (the INCI conventional name) or as AHK Copper.

Compounding. Not on the FDA bulk drug substances list for pharmaceutical compounding.

WADA. Not on the 2026 Prohibited List.

The proposed mechanism centers on copper delivery to skin and hair-follicle tissue with downstream effects on growth factor signaling and tissue remodeling.

Copper coordination and delivery. The peptide carrier solubilizes copper, protects it from precipitation, and may facilitate cellular uptake. Copper is an essential cofactor for several enzymes involved in connective tissue biology, including lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase (antioxidant), and tyrosinase (melanin synthesis). Local copper delivery through the peptide carrier provides cofactor availability for these enzymes in target tissues.

Hair-follicle effects. Cultured dermal papilla cell studies have documented AHK-Cu stimulation of VEGF production, which promotes vascularization of the hair follicle bulb. Increased blood supply to the follicle is mechanistically associated with prolonged anagen phase (active growth phase) and reduced telogen-phase shedding. The Pyo et al. work proposed this as the basis for hair-growth claims.

Skin effects. Copper-tripeptide effects on dermal fibroblasts include stimulation of collagen synthesis, elastin production, and glycosaminoglycan synthesis. The mechanism overlaps with GHK-Cu's better-characterized effects on the same cell types. Whether AHK-Cu produces effects of equivalent magnitude to GHK-Cu in matched-concentration comparisons is not well established.

Pharmacokinetics. Topical AHK-Cu absorption through intact skin is limited by molecular size and charge. Cosmetic-formulation penetration enhancers (propylene glycol, ethanol, liposomes) are used to improve dermal delivery. Systemic absorption from topical application is minimal at cosmetic concentrations. The compound is not designed for or evaluated in systemic administration in humans.

Effects reported in published in vitro and limited in vivo work:

• Stimulation of VEGF in dermal papilla cell cultures
• Increased follicular vascularization markers in animal models
• Stimulation of collagen synthesis in dermal fibroblast cultures
• Possible effects on hair-follicle anagen-phase prolongation in animal models
• Increased elastin production in dermal fibroblast cultures

Consumer and cosmetic-trade reports from finished product use describe:

• Subjective improvement in hair density and texture over multi-month use
• Possible reduction in hair shedding rates
• Subjective improvements in skin smoothness and elasticity
• Generally well-tolerated topical application

Consumer reports are uncontrolled, subject to placebo effects, and confounded by other ingredients in finished cosmetic products. Standalone AHK-Cu efficacy at cosmetic concentrations has not been rigorously isolated in controlled human studies.

Topical cosmetic concentrations for AHK-Cu in marketed products range from approximately 0.05 percent to 0.2 percent by weight. Higher concentrations (up to 1 percent) appear in research-chemical preparations and specialty hair-loss serums, but these higher concentrations are not supported by formal safety or efficacy data.

Application frequency in cosmetic protocols is typically once or twice daily, applied to clean skin or scalp. The effective absorption depth and tissue concentration achieved at standard cosmetic doses has not been comprehensively characterized.

No injectable, oral, or systemic dosing protocol for AHK-Cu exists or is supported by safety data. Some research-chemical products offer AHK-Cu as a powder for reconstitution in carrier solutions, but the absence of pharmacokinetic and safety data on systemic exposure means any non-topical use is outside the established safety envelope of the compound.

Cosmetic-grade topical AHK-Cu has an acceptable safety record in marketed formulations. Reported reactions:

• Mild local irritation at higher concentrations or with frequent application
• Rare contact dermatitis
• Possible interactions with other actives in formulation (retinoids, vitamin C, hydroxy acids may affect copper-peptide stability)
• Possible green-blue staining of fabrics or skin at high concentration from copper content

Safety concerns specific to higher-concentration use or non-topical routes:

• Copper accumulation with prolonged high-concentration topical use has not been formally characterized
• Effects in pregnancy and breastfeeding have not been evaluated
• Eye irritation potential is similar to other low-pH copper-peptide formulations
• Systemic safety from non-topical use is not characterized

Drug-drug interaction data with topical hair-loss medications (minoxidil) and other topical actives is limited. The compound is generally compatible with most cosmetic formulations but should not be combined with strong oxidizers or competing chelators that could disrupt copper coordination.

AHK-Cu is most often compared and combined with its sister compound GHK-Cu. The two peptides differ in their N-terminal residue (alanine vs glycine) and have somewhat different tissue-distribution and effect profiles in published comparative work. GHK-Cu has substantially more published research, particularly in wound healing, dermal remodeling, and gene-expression effects. AHK-Cu has a narrower documented activity focused on hair-follicle vascularization.

For hair-loss formulations specifically, AHK-Cu is often combined with GHK-Cu, and sometimes with other research-grade peptides or with established hair-loss agents (minoxidil, finasteride). The GLOW and KLOW stacks include GHK-Cu rather than AHK-Cu as their copper-peptide component.

For skin-focused cosmetic stacks, AHK-Cu appears alongside Matrixyl, Matrixyl 3000, Syn-Coll, Argireline, and SNAP-8 in multi-active formulations. The skin-cosmetic peptide category is large and the head-to-head comparative evidence is minimal. Most cosmetic decisions are guided by marketing claims, vehicle formulation, and individual response rather than by trial data.

External comparators in hair loss therapy include FDA-approved minoxidil (topical) and finasteride (oral) for androgenetic alopecia, both with substantial Phase 3 trial evidence. AHK-Cu has no comparable evidence base and is not a substitute for these established therapies in clinically significant hair loss.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.